A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Trial Profile

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Filgrastim; Paclitaxel; Pegfilgrastim
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-522
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 Jul 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Nov 2018.
    • 09 Jul 2018 Planned primary completion date changed from 1 Nov 2018 to 21 Sep 2018.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top